Does ALIROCUMAB Cause Product dose omission issue? 864 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 864 reports of Product dose omission issue have been filed in association with ALIROCUMAB (Praluent). This represents 3.8% of all adverse event reports for ALIROCUMAB.
864
Reports of Product dose omission issue with ALIROCUMAB
3.8%
of all ALIROCUMAB reports
0
Deaths
30
Hospitalizations
How Dangerous Is Product dose omission issue From ALIROCUMAB?
Of the 864 reports, 30 (3.5%) required hospitalization.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ALIROCUMAB. However, 864 reports have been filed with the FAERS database.
What Other Side Effects Does ALIROCUMAB Cause?
Myalgia (1,571)
Product dose omission (1,354)
Injection site pain (1,220)
Muscle spasms (1,113)
Arthralgia (993)
Fatigue (922)
Pain (892)
Pain in extremity (888)
Injection site bruising (821)
Device issue (785)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which ALIROCUMAB Alternatives Have Lower Product dose omission issue Risk?
ALIROCUMAB vs ALISKIREN
ALIROCUMAB vs ALISKIREN HEMIFUMARATE
ALIROCUMAB vs ALISKIREN\HYDROCHLOROTHIAZIDE
ALIROCUMAB vs ALIZAPRIDE
ALIROCUMAB vs ALLANTOIN